Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
DUBLIN, Ireland, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
-
DUBLIN, Ireland, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
-
- - -Thomas S. McHugh appointed as Chief Financial Officer- - -Dr. Jason Vaughn appointed Senior Vice President of Technical Operations DUBLIN, Ireland, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Avadel...
-
205 patients enrolled; additional patients currently in screening will be allowed to enroll if eligible Topline data from the REST-ON study expected in Q2 2020 DUBLIN, Ireland, Nov. 25, 2019 ...
-
DUBLIN, Ireland, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
-
Enrollment currently at 200 patients for the pivotal REST-ON Phase 3 study (97.5% complete); the Company currently expects to complete patient enrollment by end of 2019, with data readout expected in...
-
DUBLIN, Ireland, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
-
DUBLIN, Ireland, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, a once-nightly formulation of sodium oxybate, for narcolepsy,...
-
DUBLIN, Ireland, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate,...
-
FDA agrees with Company’s proposed changes to the statistical analysis plan for the REST-ON Phase 3 study for once-nightly sodium oxybate, FT218Reduces estimated time to completion by up to 12 months;...